Tumor progression in human malignant melanoma: Five stages defined by their antigenic phenotypes

International Journal of Cancer

Volumn 39, Issue 4, 1987, Pages 466-471

  Holzmann, Bernhard ^a   Bröcker, Eva B ^b   Lehmann, JüRgen M ^a   Ruiter, Dirk J ^c   Sorg, Clemens ^b   Riethmüller, Gert ^a   Johnson, Judith P ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; CYTOLOGY; HEREDITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; HLA ANTIGENS; HLA-D ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; MELANOMA; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEVUS; PHENOTYPE;

EID: 0023175750     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910390410     Document Type: Article

References (34)

1. Some questions and answers about dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome, and the relationship of dysplastic nevi to malignant melanoma
2. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens– new tools for genetic analysis
3. Viral oncogenes
4. Thickness, cross‐sectional areas and depth of invasion in the prognosis of cutaneous melanoma
5. Phenotypic dynamics of tumor progression in human malignant melanoma
6. Detection of phenotypic differences on human malignant melanoma lines and their variant sublines with monoclonal antibodies
7. Mutation, selection and the natural history of cancer
8. Recombinant interferon‐γ can induce the expression of HLA‐DR and ‐DC on DR‐negative melanoma cells and enhance the expression of HLA‐ABC and tumorassociated antigens
9. A study of tumor progression. The precursor lesions of superficial spreading and nodular melanoma
10. The dysplastic nevus syndrome: our definition
11. The sequential analysis of cancer development
12. The experimental study of tumor progression: A review
13. Detection of a human melanoma‐associated antigen, p97, in histological sections of primary human melanomas
14. Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome
15. Differential expression and serologically distinct subpopulations of human la antigens detected with monoclonal antibodies to la alpha and beta chains
16. Studies of a high molecular weight human melanoma‐associated antigen
17. In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89
18. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets
19. Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse origin
20. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution
21. Evolution of tumors and the impact of molecular oncology
22. Dysplastic nevi and cutaneous melanoma risk
23. Two populations of la‐like molecules on a human B cell Line
24. Cellular oncogenes and multistep carcinogenesis
25. Discrimination between benign and malignant cells of the melanocytic lineage by two novel antigens, gp113 and p76
26. Modes of binding and internalization of monoclonal anti‐melanoma antibodies
27. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma‐associated antigens and to HLA‐antigens
28. The clonal evolution of tumor cell populations
29. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues
30. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA‐antigens
31. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi
32. Binding specificity of anti‐human la monoclonal antibodies analysed with HLA‐detection mutant cell lines: Patterns of binding to products of two different HLA haplotypes and of three subregions of a single haplotype
33. A tumor‐associated antigen expressed in melanoma cells with lower malignant potential
34. Distribution and molecular characterization of a cell‐surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies